Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987895 | 0.80 | TAAR1 (0.35) | CYP2A6TAAR1 | |
| SCHEMBL23576634 | 0.74 | TAAR1 (0.31) | CYP2A6TAAR1WDR5 | |
| SCHEMBL9560864 | 0.73 | TAAR1 (0.36) | CA1CA2CA5ACA9CYP2A6 | |
| SCHEMBL6437554 | 0.72 | CYP2A6 (0.40) | CYP2A6TAAR1 | |
| SCHEMBL16102844 | 0.71 | JAK2 (0.33) | — | |
| SCHEMBL587682 | 0.68 | TAAR1 (0.42) | CYP2A6TAAR1 | |
| SCHEMBL516639 | 0.68 | WDR5 (0.44) | CA1CA2CA5ACA9CYP2A6 | |
| Magnesium SCHEMBL9306977 | 0.67 | TAAR1 (0.41) | CYP2A6TAAR1 | |
| SCHEMBL9367962 | 0.65 | KDM4E (0.37) | CYP2A6TAAR1 | |
| SCHEMBL3565013 | 0.65 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| CN-104136431-B | Pyridone and pyrimidone derivatives as plasma thromboplastin antecedent a inhibitor | 小野药品工业株式会社 | 2017-03-15 | — | — | CN | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | CA1 465/4885CA2 617/4885CA5A 408/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | CA1 465/4885CA2 617/4885CA5A 408/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | CA1 3552/4885CA2 2927/4885CA5A 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.